University of Crete (UOC)
Νέες μοριακές προσεγγίσεις για την αύξηση των επιπέδων της λιποπρωτεΐνης υψηλής πυκνότητας (HDL) στο ήπαρ και την θεραπεία της στεφανιαίας νόσου
Abstract
dc:descriptionThe aim of the present PhD thesis was to investigate the molecular mechanismsthat control the expression of genes that are involved in lipoprotein metabolism and toidentify new molecular approaches that increase HDL levels in plasma.Lipoprotein metabolism involves the transport of lipids, particularly cholesteroland triglycerides, from intestine and liver to peripheral tissues and from peripheryback to the liver (reverse cholesterol transport) and is facilitated by numerous proteinsincluding apolipoproteins, membrane transporters, plasma enzymes and lipoproteinreceptors. Lipoprotein lipase (LPL) plays a critical role in lipoprotein remodeling bycatalyzing the hydrolysis of triglycerides (TGs) present in TG-rich lipoproteinparticles such as very low density lipoprotein (VLDL) and chylomicrons (CMs) tofree fatty acids for the subsequent storage in adipose tissue or utilizations for theproduction of energy by various tissues. LPL is expressed primarily in the adiposetissue but it is also expressed at lower levels in other tissues including the liver. Therole of LPL in the adult liver has been controversial due its low levels of expressionbut recent studies in mouse models of liver LPL overexpression or deficiency haverevealed important new roles of the enzyme in glucose and lipid metabolism.In Part I we characterized the mechanism that controls the expression of humanLPL in hepatic cells at the level of transcription. First, we cloned the human LPLpromoter and performed a deletion analysis using transactivation assays in humanhepatoblastoma HepG2 cells. We revealed that the proximal region -109/-28 isimportant for basal hepatic LPL promoter activity. An in silico analysis of this regionshowed that it harbors a putative binding site, at position -47/-40, for the hepatictranscription factor forkhead box A2 (FOXA2) or Hepatocyte Nuclear factor 3β(HNF-3β), shown previously to play important roles in lipid and glucose homeostasis.Silencing of endogenous FOXA2 expression in HepG2 cells (using a specific siRNA)reduced the LPL mRNA and protein levels. Direct binding of FOXA2 to the novelbinding site was established using chromatin immunoprecipitation assays, ex vivo andDNA affinity precipitation assays in vitro. This element was further characterized bysite directed mutagenesis and it was found that five nucleotide substitutions in theFOXA2 site abolished the binding of FOXA2 and reduced the basal activity of theLPL promoter and the FOXA2-mediated transactivation. Next, we studied the effect of insulin on the hepatic regulation of the LPL gene in HepG2 cells and we showedthat insulin induces the phosphorylation of AKT and the nuclear export of FOXA2causing a reduction in the LPL mRNA levels and promoter activity. Based on thesefindings, we proposed a novel role of FOXA2 in the regulation of the human LPLgene in hepatic cells by insulin.In Part II we elucidated the mechanism of regulation of the human LPL gene byLiver X Receptors (LXR) in hepatic cells. Previous studies in mice had shown that theexpression of LPL gene in the liver is strongly induced by high fat diets and syntheticagonists that activate the nuclear receptors LXR and RXR (Retinoid X Receptor). Inagreement with these findings, we showed that treatment of HepG2 cells or primarymouse hepatocytes with the LXR synthetic agonist T0901317 upregulated theexpression of LPL gene in mRNA and protein levels. Moreover, the nuclear receptorsLXRα and RXRα transactivated strongly the human LPL promoter in response totheir ligands in HepG2 cells and deletion analysis of the human LPL promoterestablished that the minimal region required for LXR/RXR transactivation was the -109/-28, which involves the FOXA2 binding site. Interestingly, we demonstrated veryweak binding of nuclear receptors LXRα and RXRα to the proximal human LPLpromoter, using chromatin immunoprecipitation assays, suggesting that additionalfactors are required for LXR action. Silencing of the endogenous FOXA2 gene usinga specific siRNA in HepG2 cells and in mouse primary hepatocytes caused aninhibition of the oxysterol-inducible expression of LPL gene at both the mRNA andprotein levels. Importantly, insulin, which inactivates FOXA2 via its nuclearexclusion, reduced the oxysterol-inducible expression of LPL gene, indicating theimportance of FOXA2 in the lipid homeostasis in the liver. Next, we found thatFOXA2 and ligand-activated LXRα/RXRα transactivated the human LPL promoter ina synergistic fashion. The mutations in the FOXA2 binding site (-47/-40) inhibited thesynergistic transactivation of the LPL promoter by FOXA2 and LXRα/RXRα. Finally,we performed co-immunoprecipitation and GST pull down assays and establishedphysical interactions between FOXA2, LXRα and RXRα in vitro and in vivo. Anextended DNA binding domain (DBD) of LXRα is required for physical interactionswith the at least one of the two transactivation domains of FOXA2. In conclusion, thefindings of Part I and II suggest that the newly identified FOXA2 binding site in theLPL promoter serves as a novel LXRE that facilitates the induction of the LPL geneby oxysterols via FOXA2. Through an insulin-AKT-FOXA2-LPL signaling pathway the overexpression of LPL is prevented in the liver under conditions of cholesteroloverload protecting this tissue from the toxic effects of LPL.In Part III we focused on the regulation of genes that are involved in HDLbiogenesis and the remodeling by transcription factor FOXA2 and LXRs in hepaticcells. Previous studies had shown that mice heterozygous for FOXA2 have reducedlevels of HDL in the plasma. Using in silico analysis, we identified putative bindingsites for the FOXA2 factor in proximity with characterized LXR responsive elements(LXREs) in the promoters of various human HDL genes encoding the lipidtransporters ABCG1, the hepatic lipase (LIPC) and the cholesteryl ester transferprotein (CETP). In agreement with previous studies, we showed that treatment ofHepG2 cells and primary mouse hepatocytes with the synthetic LXR ligand,T0901317, caused a strong induction of mRNA levels of ABCG1, ABCG5, ABCG8and CETP genes. Inactivation of the FOXA2 factor by siRNA silencing or insulin inprimary mouse hepatocytes and HepG2 cells reduced the basal mRNA levels and alsothe induction of ABCG5 and ABCG8 genes, by T0901317, indicating that FOXA2 iscritical for the upregulation of these lipid transporters by the LXR ligands. Withtransactivation assays, we established that FOXA2 or LXRα/RXRα overexpression inthe presence of their ligands in HepG2 cells increased the activity of the promoters ofthe ABCG5 and ABCG8 genes. In agreement with these findings, silencing theexpression of LXRα or LXRβ in HepG2 cells, via lentivirus expressing shRNAsspecific for each LXR isoform, reduced the mRNA levels of ABCG8 and ABCG5genes. Furthermore, FOXA2 and ligand-activated LXRα/RXRα transactivated in asynergistic manner the promoter of ABCG8 gene, but not the ABCG5 promoter.Unexpectedly, FOXA2 inhibited the induction of the ABCG5 promoter by LXRs andoxysterols in HepG2 cells, suggesting that more distal transcription factor bindingsites far from the coding regions of the genes may be involved and via DNA loopingregulate coordinately the expression of ABCG5 and ABCG8 genes. These findingsare in line with the synergistic transactivation of LPL promoter by nuclear receptorsLXRα/RXRα and the transcription factor FOXA2, as described above.Understanding in depth the mechanisms by which lipid and glucose metabolicpathways are interconnected in the liver by factors such as FOXA2 may open the wayto novel therapeutic strategies to increase HDL levels and protect patients withmetabolic diseases such as coronary heart disease, dyslipidemia, diabetes and themetabolic syndrome.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kanaki, Maria
- Κανάκη, Μαρία
Subjects
dc:subject × 16Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40709